HALOZYME THERAPEUTICS, INC. Shareholders' Equity
HALOZYME THERAPEUTICS, INC. (HALO) had Shareholders' Equity of $143.54 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $143.54M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $219.64M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $48.81M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $503.92M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $143.54M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $219.64M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $48.81M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $503.92M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $332.75M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $482.27M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $363.82M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $452.70M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $289.42M 10-Q · filed 2025-11-03 | |
| 2024-03-31 | $177.81M 10-Q · filed 2025-08-05 | |
| 2023-12-31 | $83.81M 10-K · filed 2026-02-17 | |
| 2023-09-30 | $249.18M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $151.03M 10-Q · filed 2024-10-31 | |
| 2023-03-31 | $65.85M 10-Q · filed 2024-08-06 | |
| 2022-12-31 | $169.80M 10-K · filed 2026-02-17 | |
| 2022-09-30 | $96.99M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $293.17M 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $260.26M 10-Q · filed 2023-08-08 | |
| 2021-12-31 | $196.95M 10-K · filed 2025-02-18 | |
| 2021-09-30 | $281.67M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $119.75M 10-Q · filed 2022-11-08 | $119.75M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $67.59M 10-Q · filed 2022-08-09 | |
| 2020-12-31 | $151.05M 10-K · filed 2024-02-20 | |
| 2020-09-30 | $98.99M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $105.58M 10-Q · filed 2021-11-02 | |
| 2020-03-31 | $58.04M 10-Q · filed 2021-08-09 | |
| 2019-12-31 | $91.77M 10-K · filed 2023-02-21 | |
| 2019-09-30 | $245.35M 10-Q · filed 2020-11-02 | |
| 2019-06-30 | $260.05M 10-Q · filed 2020-11-02 | |
| 2019-03-31 | $260.05M 10-Q · filed 2020-08-10 | |
| 2018-12-31 | $248.89M 10-K · filed 2022-02-22 | |
| 2018-09-30 | $239.74M 10-Q · filed 2019-11-12 | $239.74M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $254.92M 10-Q · filed 2019-11-12 | $254.93M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $265.06M 10-Q · filed 2019-08-06 | |
| 2017-12-31 | $208.37M 10-K · filed 2021-02-23 | |
| 2017-09-30 | $72.39M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $58.16M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | -$58.50M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | -$32.48M 10-K · filed 2020-02-24 | |
| 2016-09-30 | -$11.99M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $9.92M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $29.47M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $43.00M 10-K · filed 2019-02-21 | |
| 2015-09-30 | $31.80M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $50.23M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $37.55M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $41.35M 10-K · filed 2018-02-20 | |
| 2014-09-30 | $39.94M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $55.30M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $66.75M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | -$19.99M 10-K · filed 2017-02-28 | -$19.99M 10-K · filed 2014-02-28 |
| 2013-09-30 | -$3.49M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $11.14M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $31.68M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $48.85M 10-K · filed 2016-02-29 | $48.85M 10-K · filed 2013-03-01 |
| 2012-09-30 | $51.19M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $69.23M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $81.06M 10-Q · filed 2012-05-07 | |
| 2011-12-31 | $10.90M 10-K · filed 2015-03-02 | $10.90M 10-K · filed 2012-03-12 |
| 2011-09-30 | $27.06M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $20.05M 10-Q · filed 2011-08-05 | |
| 2010-12-31 | $20.35M 10-K · filed 2014-02-28 | |
| 2009-12-31 | $6.90M 10-K · filed 2013-03-01 | |
| 2008-12-31 | $15.38M 10-K · filed 2012-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |